

Publications 2014-2015 Etudes et Recherche en Economie de la Santé

1. Borget I, Bonastre J, Catargi B, Déandréis D, Zerdoud S, Rusu D, Bardet S, Leenhardt L, Bastie D, Schvartz C, Vera P, Morel O, Benisvy D, Bournaud C, Bonichon F, Kelly A, Toubert ME, Leboulleux S, Journeau F, Benhamou E, Schlumberger M. Quality of life and cost-effectiveness assessment of radioiodine ablation strategies in thyroid cancer patients: results from the randomized phase III ESTIMABL trial. **J Clin Oncol** 2015; 33(26):2885-92
2. Bonastre J, Marguet S, Lueza B, Michiels S, Delalogue S, Saghatchian M. Reply to V.P. Retèl et al, D. Gauchan et al, and C. Rahilly-Tierney et al. **J Clin Oncol**. 2015;33(14):1629-30.
3. Martelli N, Billaux M, Borget I, Pineau J, Prognon P, van den Brink H. Introduction of innovative medical devices at French university hospitals: an overview of hospital-based health technology assessment initiatives. **Int J Technol Assess Health Care**. 2015;31(1-2):12-8.
4. Martelli N, Devaux C, van den Brink H, Pineau J, Prognon P, Borget I. A Systematic Review of the Level of Evidence in Economic Evaluations of Medical Devices: The Example of Vertebroplasty and Kyphoplasty. **PLoS One**. 2015 Dec 10;10(12)
5. Scotte F, Martelli N, Vainchtock A, Borget I. The cost of thromboembolic events in hospitalized patients with breast or prostate cancer in France. **AdvTher**. 2015;32(2):138-47.
6. Luporsi E, Bellocq JP, Barrière J, Bonastre J, Chetritt J, Le Corroller AG, de Cremoux P, Fina F, Gauchez AS, Lamy PJ, Martin PM, Mazouni C, Peyrat JP, Romieu G, Verdoni L, Mazeau-Woynar V, Kassab-Chahmi D. [uPA/PAI-1, Oncotype DX™, MammaPrint®]. Prognosis and predictive values for clinical utility in breast cancer management]. **Bull Cancer**. 2015. pii: S0007-4551(15)00203-9.
7. Bellocq JP, Luporsi E, Barrière J, Bonastre J, Chetritt J, Le Corroller AG, de Crémoux P, Fina F, Gauchez AS, Kassab-Chahmi D, Lamy PJ, Martin PM, Mazouni C, Peyrat JP, Romieu G, Verdoni L, Mazeau-Woynar V. [uPA/PAI-1, Oncotype DX™, MammaPrint®]. Prognosis and predictive values for clinical utility in breast cancer management]. **Ann Pathol**. 2014 Oct;34(5):349-51.
8. Bonastre J, Marguet S, Lueza B, Michiels S, Delalogue S, Saghatchian M. Cost effectiveness of molecular profiling for adjuvant decision making in patients with node-negative breast cancer. **J Clin Oncol**. 2014;32(31):3513-9.
9. Chouaid C, Borget I, Vergnenegre A. Targeted therapies in non-small-cell lung cancer management: no cost-effective strategies? **J Clin Oncol** 2014; 32: 3577.
10. Lassau N, Bonastre J, Kind M, Vilgrain V, Lacroix J, Cuinet M, Taieb S, Aziza R, Sarran A, Labbe-Devilliers C, Gallix B, Lucidarme O, Ptak Y, Rocher L, Caquot LM, Chagnon S, Marion D, Luciani A, Feutray S, Uzan-Augui J, Coiffier B, Benastou B, Koscielny S. Validation of Dynamic Contrast-Enhanced Ultrasound in Predicting Outcomes of Antiangiogenic Therapy for Solid Tumors: The French Multicenter Support for Innovative and Expensive Techniques Study. **Invest Radiol**. 2014;49(12):794-800.

11. Bonastre J, Chevalier J, Van der Laan C, Delibes M, De Pouvourville G. Access to innovation: is there a difference in the use of expensive anticancer drugs between French hospitals? **Health Policy**. 2014;116(2-3):162-9.
12. Scotte F, Martelli N, Vainchtock A, Borget I. The cost of thromboembolic events in hospitalized patients with breast or prostate cancer in France. **Adv Ther** 2015. 32;138-47.
13. Borget I, Pérol M, Pérol D, Lavolé A, Greillier L, Dô P, Westeel V, Crequit J, Léna H, Monnet I, Le Caer H, Fournel P, Falchero L, Poudenx M, Vaylet F, Chabaud S, Vergnenegre A, Zalcman G, Chouaïd C, IFCT-GFPC investigators. Cost-utility analysis of maintenance therapy with gemcitabine or erlotinib vs observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy for advanced NSCLC: IFCT-GFPC 0502-Eco phase III study. **BMC Cancer** 2014; 14: 953.
14. Borget I, Antoun S, Chachaty E, Gachot B, Alibay A, Di Palma M, Merad M. Modalités de prise en charge des neutropénies fébriles chez les patients traités pour une néoplasie solide dans le service d'urgence de cancérologie Gustave-Roussy et leurs impacts économiques. **Bull Cancer** 2014 ;101 : 925-31.